

Normal Tissue Type
BRCA84D 0.625 µg/ml
BRCA84D 0.078 µg/ml
Pancreas
Liver
Lung
Colon

Figure 1A




Normal Tissue Type	BRCA84D 0.625 µg/ml
Heart	
Kidney	
Adrenal	

Figure 1B



Cancer Tissue Type
BRCA84D 0.625 µg/ml
BRCA84D 0.078 µg/ml
Prostate
Breast
Colon
Lung

Figure 2




Figure 3A




Figure 3B




Figure 3C




Figure 3D




Figure 4A




Figure 4B




Figure 5A




Figure 5B




Figure 5C




Figure 5D




Figure 5E




Figure 5F




Figure 5G




Figure 5H




Figure 5I




Figure 5J




Figure 5K




Figure 5L




Figure 5M




Figure 5N




Figure 5O




Figure 5P




Figure 5Q




Figure 5R




Figure 5S




Figure 6A




Figure 6B




Figure 6C




Figure 6D




Figure 6E




Figure 6F




Figure 6G




Figure 6H




Figure 6I




Figure 7




Figure 8




Figure 9A




Figure 9B




Figure 10A




Figure 10B




Figure 10C




Figure 10D




Figure 10E






Figure 10F



(1) BRCA84D Variable Light Chain (SEQ ID NO:3)
(2) Humanized BRCA84D-1 Variable Light Chain (SEQ ID NO:68)

Figure 11A



(1) BRCA84D Variable Heavy Chain (SEQ ID NO:11)
(2) Humanized BRCA84D-1 Variable Heavy Chain (SEQ ID NO:80)

Figure 11B




Figure 12




Figure 13



hBRCA84D Binding Elisa
OD450 nM
2.0
1.5
1.0
0.5
0.0
1
10
100
1000
mAb concentration (ng/ml)
hBRCA84D-2VL
hBRCA84D-2VH (1)
hBRCA84D-2VL
hBRCA84D-2VH (2)
chBRCA84D
hBRCA84D-5VL
ch BRCA84D
hBRCA84D-5VL
hBRCA84D-2VH

Figure 14



HT-1197 Urinary Bladder Carcinoma
Tumor Volume (mm3)
600
500
400
300
200
100
0
0
10
20
30
40
50
60
70
Days
Vehicle
IgG Control
hBRCA84D-2 (L235V, F243L, R292P, Y300L, and P396L) (1 mg/kg)
hBRCA84D-2 (L235V, F243L, R292P, Y300L, and P396L) (10 mg/kg)
hBRCA84D-2 (L235V, F243L, R292P, Y300L, and P396L) (20 mg/kg)

Figure 15





A498 Renal Carcinoma Cell
Tumor Volume (mm3)
1200
1000
800
600
400
200
0
0
10
20
30
40
50
Days
***
***
***
*
***
***
**
Vehicle
IgG Control (10 mg/kg)
hBRCA84D-2 (L235V, F243L, R292P, Y300L, and P396L) (1 mg/kg)
hBRCA84D-2 (L235V, F243L, R292P, Y300L, and P396L) (10 mg/kg)
hBRCA84D-2 (L235V, F243L, R292P, Y300L, and P396L) (20 mg/kg)

Figure 16




▲ hBRCA84D-2 / TCR DART
○ hBRCA84D-2 (L235V, F243L, R292P, Y300L, and P396L)
■ hBRCA84D-2
◇ TDART control

Figure 17A




▲ hBRCA84D-2 / TCR DART
○ hBRCA84D-2 (L235V, F243L, R292P, Y300L, and P396L)
■ hBRCA84D-2
◇ TDART control

Figure 17B



▲ hBRCA84D-2 / TCR DART
○ hBRCA84D-2 (L235V, F243L, R292P, Y300L, and P396L)
■ hBRCA84D-2
◇ TDART control

Figure 17C



▲ hBRCA84D-2 / TCR DART
○ hBRCA84D-2 (L235V, F243L, R292P, Y300L, and P396L)
■ hBRCA84D-2
◇ TDART control

Figure 17D




Figure 18A




Figure 18B




Figure 18C




Figure 19




Figure 20




Figure 21A




Figure 21B




Figure 21C




Figure 22A




Figure 22B




Figure 23




Figure 24




Figure 25




Figure 26




Figure 27




Figure 28A




Figure 28B




Figure 28C




Figure 29




Figure 30A




Figure 30B




Figure 30C




Figure 31




Figure 32




Figure 33A



Tumor Volume (mm3)
800
700
600
500
400
300
200
100
0
0
10
20
30
40
50
Study Day
Vehicle
IgG (10 mg/kg)
Cetuximab (1 mg/kg)
Cetuximab (7 mg/kg)
Cetuximab (15 mg/kg)

Figure 33B



Vehicle
IgG Control (5 mg/kg)
Mab1 (0.1 mg/kg)
Mab1 (0.5 mg/kg)
Mab1 (1 mg/kg)
Mab1 (5 mg/kg)
Mab1 (10 mg/kg)
Paclitaxel (2.5 mg/kg)
Tumor Volume (mm3)
2000
1800
1600
1400
1200
1000
800
600
400
200
0
0
10
20
30
40
50
60
70
80
90
Study Day

Figure 34